Subscribe to our Email Alerts

Amplia Therapeutics Limited

Amplifying Oncology Treatments

Learn more

Amplia Therapeutics Limited

Focal Adhesion Kinase: A New Target in the Fight Against Cancer

Learn more

Amplia Therapeutics Limited

Focus on Fibrotic Cancers and Fibrosis

Learn more
 

A new approach for treating cancer and fibrotic diseases​

Amplia is a clinical-stage company developing small molecule inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases​.
To view the latest Amplia Therapeutics Limited's Investor Presentation click here Read More

Latest Presentations

Latest ASX Announcements

Media Releases

ASX Share Price

Market Cap:
Price Delay ~20min
Amplia Therapeutics recognises and respects First Nations People and welcomes the work of all those who strive for health equality in Australia